These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24824628)

  • 1. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
    Zhang J; Wang Z; Hu X; Wang B; Wang L; Yang W; Liu Y; Liu G; Di G; Hu Z; Wu J; Shao Z
    Int J Cancer; 2015 Jan; 136(1):204-11. PubMed ID: 24824628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC
    Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
    Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
    Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
    Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
    Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.
    Ozkan M; Berk V; Kaplan MA; Benekli M; Coskun U; Bilici A; Gumus M; Alkis N; Dane F; Ozdemir NY; Colak D; Dikilitas M
    Neoplasma; 2012; 59(1):38-42. PubMed ID: 22103897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
    Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD
    Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
    Wang B; Sun T; Zhao Y; Wang S; Zhang J; Wang Z; Teng YE; Cai L; Yan M; Wang X; Jiang Z; Pan Y; Luo J; Shao Z; Wu J; Guo X; Hu X
    Nat Commun; 2022 Jul; 13(1):4025. PubMed ID: 35821019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
    Yardley DA; Coleman R; Conte P; Cortes J; Brufsky A; Shtivelband M; Young R; Bengala C; Ali H; Eakel J; Schneeweiss A; de la Cruz-Merino L; Wilks S; O'Shaughnessy J; Glück S; Li H; Miller J; Barton D; Harbeck N;
    Ann Oncol; 2018 Aug; 29(8):1763-1770. PubMed ID: 29878040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline
    O'Reilly EM; Lee JW; Zalupski M; Capanu M; Park J; Golan T; Tahover E; Lowery MA; Chou JF; Sahai V; Brenner R; Kindler HL; Yu KH; Zervoudakis A; Vemuri S; Stadler ZK; Do RKG; Dhani N; Chen AP; Kelsen DP
    J Clin Oncol; 2020 May; 38(13):1378-1388. PubMed ID: 31976786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
    O'Shaughnessy J; Schwartzberg L; Danso MA; Miller KD; Rugo HS; Neubauer M; Robert N; Hellerstedt B; Saleh M; Richards P; Specht JM; Yardley DA; Carlson RW; Finn RS; Charpentier E; Garcia-Ribas I; Winer EP
    J Clin Oncol; 2014 Dec; 32(34):3840-7. PubMed ID: 25349301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
    Li Y; Zhao Y; Gong C; Xie Y; Hu X; Zhang J; Wang L; Zhang S; Cao J; Tao Z; Wang B
    Sci Rep; 2019 Mar; 9(1):3563. PubMed ID: 30837503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
    Erten C; Demir L; Somali I; Alacacioglu A; Kucukzeybek Y; Akyol M; Can A; Dirican A; Bayoglu V; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(6):3711-7. PubMed ID: 23886170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
    Hahn NM; Stadler WM; Zon RT; Waterhouse D; Picus J; Nattam S; Johnson CS; Perkins SM; Waddell MJ; Sweeney CJ;
    J Clin Oncol; 2011 Apr; 29(12):1525-30. PubMed ID: 21422406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
    Li Q; Li Q; Zhang P; Yuan P; Wang J; Ma F; Luo Y; Fan Y; Cai R; Xu B
    Cancer Biol Ther; 2015; 16(12):1746-53. PubMed ID: 26466918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
    Kang MJ; Lee JL; Kim TW; Lee SS; Ahn S; Park DH; Lee SS; Seo DW; Lee SK; Kim MH
    Acta Oncol; 2012 Sep; 51(7):860-6. PubMed ID: 22559158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
    Du F; Yuan P; Luo Y; Wang J; Ma F; Cai R; Fan Y; Li Q; Zhang P; Xu B
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):788-92. PubMed ID: 26813602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.